Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis With Biologics to Clinical Practice

Deeti J. Pithadia, BS; Kelly A. Reynolds, BA; Erica B. Lee, MD; Jashin J. Wu, MD

Psoriasis is a systemic immune-mediated disorder characterized by erythematous, scaly, well-demarcated plaques on the skin that affects approximately 3% of the world’s population. The disease is moderate to severe for approximately 1 in 6 individuals with psoriasis. These patients, particularly those with symptoms that are refractory to topical therapy and/or phototherapy, can benefit from the use of biologic agents, which are monoclonal antibodies and fusion proteins engineered to inhibit the action of cytokines that drive psoriatic inflammation.

In February 2019, the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) released an updated set of guidelines for the use of biologics in treating adult patients with psoriasis. The prior guidelines were released in 2008 when just 3 biologics—etanercept, infliximab, and adalimumab—were approved by the US Food and Drug Administration (FDA) for the management of psoriasis. These older recommendations were mostly based on studies of the efficacy and safety of biologics for patients with psoriatic arthritis. Over the last 11 years, 8 novel biologics have gained FDA approval, and numerous large phase 2 and phase 3 trials evaluating the risks and benefits of biologics have been conducted. The new guidelines contain considerably more detail and are based on evidence more specific to psoriasis rather than to psoriatic arthritis. Given the large repertoire of biologics available today and the increased amount of published research regarding each one, these guidelines provide the most current evidence regarding the dosing, indications, contraindications, and adverse effects of each therapy. This review aims to present the recommendations in a form that is readily translatable to clinical practice.


PRACTICE POINTS

- There are currently 11 biologics approved for psoriasis, but there is no first-line or optimal biologic. The choice must be made using clinical judgment based on a variety of medical and social factors.
- Frequent assessment for efficacy of and adverse events due to biologic therapy is warranted, as lack of response, loss of response, or severe side effects may warrant addition of concurrent therapies or switching to a different biologic.
- There are important considerations to make when immunizing and planning for surgery in patients on biologics.

Ms. Pithadia is from Medical College of Georgia, Augusta University. Ms. Reynolds is from University of Cincinnati College of Medicine, Ohio. Dr. Lee is from the Department of Medicine, Santa Barbara Cottage Hospital, California. Dr. Wu is from Dermatology Research and Education Foundation, Irvine, California.

Ms. Pithadia, Ms. Reynolds, and Dr. Lee report no conflict of interest. Dr. Wu is an investigator for AbbVie, Amgen Inc, Eli Lilly and Company, Janssen Pharmaceuticals, and Novartis. He also is a consultant for AbbVie; Almiral; Amgen Inc; Bristol-Myers Squibb; Celgene Corporation; Dermira Inc; Dr. Reddy’s Laboratories Ltd; Eli Lilly and Company; Janssen Pharmaceuticals; LEO Pharma; Novartis; Promius Pharma; Regeneron Pharmaceuticals, Inc; Sun Pharmaceutical Industries Ltd; UCB; and Valeant Pharmaceuticals North America LLC. He also is a speaker for AbbVie; Celgene Corporation; Novartis; Regeneron Pharmaceuticals, Inc; Sanofi Genzyme; Sun Pharmaceutical Industries Ltd; UCB; and Valeant Pharmaceuticals North America LLC.

Correspondence: Jashin J. Wu, MD (jashinwu@gmail.com).
Choosing a Biologic

Biologic therapy may be considered for patients with psoriasis that affects more than 3% of the body’s surface and is recalcitrant to localized therapies. There is no particular first-line biologic recommended for all patients with psoriasis; rather, choice of therapy should be individualized to the patient, considering factors such as body parts affected, comorbidities, lifestyle, and drug cost.

All 10 FDA-approved biologics (Table) have been ranked by the AAD and NPF as having grade A evidence for efficacy as monotherapy in the treatment of moderate to severe plaque-type psoriasis. Involvement of difficult-to-treat areas may be considered when choosing a specific therapy. The tumor necrosis factor α (TNF-α) inhibitors etanercept and adalimumab, the IL-17 inhibitor secukinumab, and the IL-23 inhibitor guselkumab have the greatest evidence for efficacy in treatment of nail disease. For scalp involvement, etanercept and guselkumab have the highest quality evidence, and for palmoplantar disease, adalimumab, secukinumab, and guselkumab are considered the most effective. The TNF-α inhibitors are considered the optimal treatment option for concurrent psoriatic arthritis, though the IL-12/IL-23 inhibitor ustekinumab and the IL-17 inhibitors secukinumab and ixekizumab also have shown grade A evidence of efficacy. Of note, because TNF-α inhibitors received the earliest FDA approval, there is most evidence available for this class. Therapies with lower evidence quality for certain forms of psoriasis may show real-world effectiveness in individual patients, though more trials will be necessary to generate a body of evidence to change these clinical recommendations.

In pregnant women or those who are anticipating pregnancy, certolizumab may be considered, as it is the only biologic shown to have minimal to no placental transfer. Other TNF-α inhibitors may undergo active placental transfer, particularly during the latter half of pregnancy, and the greatest theoretical risk of transfer occurs in the third trimester. Although these drugs may not directly harm the fetus, they do cause fetal immunosuppression for up to the first 3 months of life. All TNF-α inhibitors are considered safe during lactation. There are inadequate data regarding the safety of other classes of biologics during pregnancy and lactation.

Overweight and obese patients also require unique considerations when choosing a biologic. Infliximab is the only approved psoriasis biologic that utilizes proportional-to-weight dosing and hence may be particularly efficacious in patients with higher body mass. Ustekinumab dosing also takes patient weight into consideration; patients heavier than 100 kg should receive 90-mg doses at initiation and during maintenance compared to 45 mg for patients who weigh 100 kg or less. Other approved biologics also may be utilized in these patients but may require closer monitoring of treatment efficacy.

There are few serious contraindications for specific biologic therapies. Any history of allergic reaction to a particular therapy is an absolute contraindication to its use. In patients for whom IL-17 inhibitor treatment is being considered, inflammatory bowel disease (IBD) should be ruled out given the likelihood that IL-17 could reactivate or worsen IBD. Of note, TNF-α inhibitors and ustekinumab are approved therapies for patients with IBD and may be recommended in patients with comorbid psoriasis. Phase 2 and phase 3 trials have found no reactivation or worsening of IBD in patients with psoriasis who were treated with the IL-23 inhibitor tildrakizumab, and phase 2 trials of treatment of IBD for whom IL-17 inhibitor treatment is being considered, a total of 3 patients died by suicide; hence, the FDA has issued a black box warning cautioning against use of this drug in patients with history of suicidal ideation or recent suicidal behavior. Although a causal relationship between brodalumab and suicide has not been well established, a thorough psychiatric history should be obtained in those initiating treatment with brodalumab.

Initiation of Therapy

Prior to initiating biologic therapy, it is important to obtain a complete blood cell count, complete metabolic panel, tuberculosis testing, and hepatitis B virus (HBV) and hepatitis C virus serologies. Testing for human immunodeficiency virus may be pursued at the clinician’s discretion. It is important to address any positive or concerning results prior to starting biologics. In patients with active infections, therapy may be initiated alongside guidance from an infectious disease specialist. Those with a positive purified protein derivative test, T-SPOT test, or QuantiFERON-TB Gold test must be referred for chest radiographs to rule out active tuberculosis. Patients with active HBV infection should receive appropriate referral.
# Summary of FDA-Approved Biologics for Psoriasis<sup>a</sup>

<table>
<thead>
<tr>
<th>Biologic</th>
<th>Mechanism of Action</th>
<th>Half-life, d</th>
<th>Mode of Therapy</th>
<th>Recommended Initiation Dosing</th>
<th>Recommended Maintenance Dosing</th>
<th>Recommended Dosing Adjustments</th>
<th>Recommended Time Frame to Assess for Initial Therapeutic Response, wk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etanercept</td>
<td>Decoy receptor for soluble TNF-α</td>
<td>3.5</td>
<td>Subcutaneous injection</td>
<td>50 mg twice weekly for 12 consecutive weeks</td>
<td>50 mg once weekly</td>
<td>50 mg twice weekly if poor response</td>
<td>12</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Chimeric (mouse + human) monoclonal antibody that binds soluble and transmembrane TNF-α</td>
<td>10</td>
<td>Intravenous infusion</td>
<td>5 mg/kg at wk 0, 2, and 6</td>
<td>5 mg/kg every 8 wk</td>
<td>Up to 10 mg/kg and/or as frequent as every 4 wk if poor response</td>
<td>16</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>Human monoclonal antibody that binds soluble and transmembrane TNF-α</td>
<td>14</td>
<td>Subcutaneous injection</td>
<td>80 mg at wk 0, followed by 40 mg at wk 1</td>
<td>40 mg every 2 wk</td>
<td>40 mg once weekly if poor response</td>
<td>12</td>
</tr>
<tr>
<td>Certolizumab</td>
<td>Humanized antigen binding monoclonal antibody fragment conjugated with a moiety that binds TNF-α</td>
<td>14</td>
<td>Subcutaneous injection</td>
<td>If ≤90 kg: 400 mg at wk 0, 2, and 4; if &gt;90 kg: 400 mg at wk 0</td>
<td>If ≤90 kg: 200 mg every other week; if &gt;90 kg: 400 mg every 2 wk</td>
<td>NA</td>
<td>12</td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>Human monoclonal antibody that binds p40 subunit of IL-12/IL-23</td>
<td>21</td>
<td>Subcutaneous injection</td>
<td>If ≤100 kg: 45 mg at wk 0 and 4; if &gt;100 kg: 90 mg at wk 0 and 4</td>
<td>If ≤100 kg: 45 mg every 12 wk; if &gt;100 kg: 90 mg every 12 wk</td>
<td>Up to 90 mg every 12 wk if ≤100 kg or dosing every 8 wk if poor response</td>
<td>12</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>Human monoclonal antibody that binds IL-17A</td>
<td>27</td>
<td>Subcutaneous injection</td>
<td>300 mg weekly for 5 consecutive weeks</td>
<td>300 mg every 4 wk</td>
<td>NA</td>
<td>12</td>
</tr>
<tr>
<td>Ixekizumab</td>
<td>Humanized monoclonal antibody that neutralizes IL-17A</td>
<td>13</td>
<td>Subcutaneous injection</td>
<td>160 mg at wk 0 followed by 80 mg every 2 wk for 12 consecutive weeks</td>
<td>80 mg every 4 wk</td>
<td>NA</td>
<td>12</td>
</tr>
<tr>
<td>Brodalumab</td>
<td>Human monoclonal antibody that binds IL-17A and blocks activity of IL-17A, IL-17F, IL-17AF, and IL-17E</td>
<td>11</td>
<td>Subcutaneous injection</td>
<td>210 mg at wk 0, 1, and 2</td>
<td>210 mg every 2 wk</td>
<td>NA</td>
<td>12</td>
</tr>
<tr>
<td>Guselkumab</td>
<td>Human monoclonal antibody that blocks p19 subunit of IL-23</td>
<td>18</td>
<td>Subcutaneous injection</td>
<td>100 mg at wk 0 and 4</td>
<td>100 mg every 8 wk</td>
<td>NA</td>
<td>12</td>
</tr>
<tr>
<td>Tildrakizumab</td>
<td>Humanized monoclonal antibody that blocks p19 subunit of IL-23</td>
<td>23</td>
<td>Subcutaneous injection</td>
<td>100 mg at wk 0 and 4</td>
<td>100 mg every 12 wk</td>
<td>NA</td>
<td>12</td>
</tr>
</tbody>
</table>

Abbreviations: FDA, US Food and Drug Administration; TNF, tumor necrosis factor; NA, not applicable; AAD, American Academy of Dermatology; NPF, National Psoriasis Foundation.

<sup>a</sup>As of March 2019 and based on joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
to initiate antiviral therapy as well as core antibody testing, and those with active hepatitis C virus infection may only receive biologics under the combined discretion of a dermatologist and an appropriate specialist. Patients with human immunodeficiency virus must concurrently receive highly active antiretroviral therapy, show normal CD4+ T-cell count and undetectable viral load, and have no recent history of opportunistic infection.

Therapy should be commenced using specific dosing regimens, which are unique for each biologic (Table). Patients also must be educated on routine follow-up to assess treatment response and tolerability.

**Assessment and Optimization of Treatment Response**

Patients taking biologics may experience primary treatment failure, defined as lack of response to therapy from initiation. One predisposing factor may be increased body mass; patients who are overweight and obese are less likely to respond to standard regimens of TNF-α inhibitors and 45-mg dosing of ustekinumab. In most cases, however, the cause of primary nonresponse is unpredictable. For patients in whom therapy has failed within the recommended initial time frame (Table), dose escalation or shortening of dosing intervals may be pursued. Recommended dosing adjustments are outlined in the Table. Alternatively, patients may be switched to a different biologic.

If desired effectiveness is not reached with biologic monotherapy, topical corticosteroids, topical vitamin D analogues, or narrowband UVB light therapy may be concurrently used for difficult-to-treat areas. Evidence for safety and effectiveness of systemic adjuncts to biologics is moderate to low, warranting caution with their use. Methotrexate, cyclosporine, and apremilast have synergistic effects with biologics, though they may increase the risk for immunosuppression-related complications. Acitretin, an oral retinoid, likely is the most reasonable systemic adjunct to biologics because of its lack of immunosuppressive properties.

In patients with a suboptimal response to biologics, particularly those taking therapies that require frequent dosing, poor compliance should be considered. These patients may be switched to a biologic with less-frequent maintenance dosing (Table). Ustekinumab and tildrakizumab may be the best options for optimizing compliance, as they require dosing only once every 12 weeks after administration of loading doses.

Secondary treatment failure is diminished efficacy of treatment following successful initial response despite no changes in regimen. The best-known factor contributing to secondary nonresponse to biologics is the development of antidrug antibodies (ADAs), a phenomenon known as immunogenicity. The development of efficacy-limiting ADAs has been observed in response to most biologics, though ADAs against etanercept and guselkumab do not limit therapeutic response. Patients taking adalimumab and infliximab have particularly well-documented efficacy-limiting immunogenicity, and those who develop ADAs to infliximab are considered more prone to developing infusion reactions. Methotrexate, which limits antibody formation, may concomitantly be prescribed in patients who experience secondary treatment failure. It should be considered in all patients taking infliximab to increase efficacy and tolerability of therapy.

**Considerations During Active Therapy**

In addition to monitoring adherence and response to regimens, dermatologists must be heavily involved in counseling patients regarding the risks and adverse effects associated with these therapies. During maintenance therapy with biologics, patients must follow up with the prescriber at minimum every 3 to 6 months to evaluate for continued efficacy of treatment, extent of side effects, and effects of treatment on overall health and quality of life. Given the immunosuppressive effects of biologics, annual testing for tuberculosis should be considered in high-risk individuals. In those who are considered at low risk, tuberculosis testing may be done at the discretion of the dermatologist. In those with a history of HBV infection, HBV serologies should be pursued routinely given the risk for reactivation.

Annual screening for nonmelanoma skin cancer should be performed in all patients taking biologics. Tumor necrosis factor α inhibitor therapy in particular confers an elevated risk for cutaneous squamous cell carcinoma, especially in patients who are immunosuppressed at baseline and those with history of UV phototherapy. Use of acitretin alongside TNF-α inhibitors or ustekinumab may prevent squamous cell carcinoma formation in high-risk patients.

Because infliximab treatment poses an elevated risk of liver injury, liver function tests should be repeated 3 months following initiation of treatment and then every 6 to 12 months subsequently if results are normal. Periodic assessment of suicidal ideation is recommended in patients on brodalumab therapy, which may necessitate more frequent follow-up visits and potentially psychiatry referrals in certain patients. Patients taking IL-17 inhibitors, particularly those who are concurrently taking methotrexate, are at increased risk for developing mucocutaneous *Candida* infections; these patients should be monitored for such infections and treated appropriately.

It is additionally important for prescribing dermatologists to ensure that patients on biologics are following up with their general providers to receive timely age-appropriate preventative screenings and vaccines. Inactivated vaccinations may be administered during therapy with any biologic; however, live vaccinations may induce systemic infection in those who are immunocompromised, which theoretically includes individuals taking biologic agents, though incidence data in this patient population are scarce. Some experts believe that administration of live vaccines warrants temporary discontinuation.
of biologic therapy for 2 to 3 half-lives before and after vaccination (Table). Others recommend stopping treat-
ment at least 4 weeks before and until 2 weeks after vaccination. For patients taking biologics with half-lives
greater than 20 days, which would theoretically require
stopping the drug 2 months prior to vaccination, the ben-
efit of vaccination should be weighed against the risk of
prolonged discontinuation of therapy. Until recently, this
recommendation was particularly important, as a live her-
pes zoster vaccination was recommended by the Centers
for Disease Control and Prevention for adults older than
60 years. In 2017, a new inactivated herpes zoster vaccine
was introduced and is now the preferred vaccine for all
patients older than 50 years.14 It is especially important
that patients on biologics receive this vaccine to avoid
temporary drug discontinuation.

Evidence that any particular class of biologics increases
risk for solid tumors or lymphoreticular malignancy is
limited. One case-control analysis reported that more
than 12 months of treatment with TNF-α inhibitors may
increase risk for malignancy; however, the confidence
interval reported hardly allows for statistical significance.15
Another retrospective cohort study found no elevated inci-
dence of cancer in patients on TNF-α inhibitors compared
to nonbiologic comparators.16 Ustekinumab was shown to
confer no increased risk for malignancy in 1 large study,15
but no large studies have been conducted for other classes
of drugs. Given the limited and inconclusive evidence
available, the guidelines recommend that age-appropriate
cancer screenings recommended for the general popula-
tion should be pursued in patients taking biologics.

Surgery while taking biologics may lead to stress-
induced augmentation of immunosuppression, resulting
in elevated risk of infection.17 Low-risk surgeries that
do not warrant discontinuation of treatment include
endoscopic, ophthalmologic, dermatologic, orthopedic,
and breast procedures. In patients preparing for elective
surgery in which respiratory, gastrointestinal, or genito-
urinary tracts will be entered, biologics may be discon-
tinued at least 3 half-lives (Table) prior to surgery if the
dermatologist and surgeon collaboratively deem that risk
of infection outweighs benefit of continued therapy.18
Therapy may be resumed within 1 to 2 weeks postopera-
tively if there are no surgical complications.

Switching Biologics
Changing therapy to another biologic should be considered
if there is no response to treatment or the patient experi-
ences adverse effects while taking a particular biologic.
Because evidence is limited regarding the ideal time frame
between discontinuation of a prior medication and initia-
tion of a new biologic, this interval should be determined at
the discretion of the provider based on the patient’s disease
severity and response to prior treatment. For individuals
who experience primary or secondary treatment failure
while maintaining appropriate dosing and treatment com-
pliance, switching to a different biologic is recommended
to maximize treatment response.19 Changing therapy to a
biologic within the same class is generally effective,20 and
switching to a biologic with another mechanism of action
should be considered if a class-specific adverse effect is the
major reason for altering the regimen. Nonetheless, some
patients may be unresponsive to biologic changes. Further
research is necessary to determine which biologics may be
most effective when previously used biologics have failed
and particular factors that may predispose patients to bio-
logic unresponsiveness.

Resuming Biologic Treatment
Following Cessation
In cases where therapy is discontinued for any reason, it
may be necessary to repeat initiation dosing when resum-
ing treatment. In patients with severe or flaring disease or if
more than 3 to 4 half-lives have passed since the most recent
dose, it may be necessary to restart therapy with the loading
dose (Table). Unfortunately, restarting therapy may preclude
some patients from experiencing the maximal response that
they attained prior to cessation. In such cases, switching bio-
logic therapy to a different class may prove beneficial.

Final Thoughts
These recommendations contain valuable information
that will assist dermatologists when initiating biologics
and managing outcomes of their psoriasis patients. It is,
however, crucial to bear in mind that these guidelines
serve as merely a tool. Given the paucity of comprehensive
research, particularly regarding some of the more recently
approved therapies, there are many questions that are
unanswered within the guidelines. Their utility for each
individual patient situation is therefore limited, and clini-
cal judgement may outweigh the information presented.
The recommendations nevertheless provide a pivotal and
unprecedented framework that promotes discourse among
patients, dermatologists, and other providers to optimize
the efficacy of biologic therapy for psoriasis.

REFERENCES
1. Michalek JM, Loring B, John SM. A systematic review of worldwide epi-
2. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
care for the management and treatment of psoriasis with biologics [pub-
management of psoriasis and psoriatic arthritis: section 1. overview
of psoriasis and guidelines of care for the treatment of psoriasis with
5. Forger F, Villiger PM. Treatment of rheumatoid arthritis during preg-
diagnosed and undiagnosed psoriasis in US adults: results from NHANES
7. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
8. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
9. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
10. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
11. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
12. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
13. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
14. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
15. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
16. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
17. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
18. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
19. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and
20. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and